CID16020046 | GPR55 antagonist
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $60.00 | ||
| 25 mg | $200.00 |
CID16020046 (834903-43-4) is a selective GPR55 antagonist.1 In HEK293 cells expressing GPR55, the compound behaves as an antagonist on lysophosphatidylinositol (LPI)-mediated Ca2+ release but was inactive on cells expressing CB1 and CB2. It blocks LPI-induced migration of colon cancer cells.2 It displays protective effects against oxidized LDL-induced inflammation3, mitigates advanced glycation end products-induced chondrocyte activation4, and displays anti-inflammatory effects in various cells5,6. A useful tool for studying the role of GPR55 in cellular physiology.
References/CItations:
- Kargl et al. (2013), A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function; J. Pharmacol. Exp. Ther. 346 54
- Kargl et al. (2016), GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis; Br. J. Pharmacol. 173 142
- Wang et al. (2020), The GPR55 antagonist CID16020046 protects against ox-LDL-induced inflammation in human aortic endothelial cells (HAECs); Arch. Biochem. Biophys. 681 108254
- Zeng et al. (2020), The GPR55 antagonist CID16020046 mitigates advanced glycation end products (AGEs)- induced chondrocyte activation; Chem. Biol. Interact. 325 109088
- Minamihata et al. (2020), Lysophosphatidylinositol, an Endogenous Ligand for G Protein-Coupled Receptor 55, Has Anti-inflammatory Effects in Cultured Microglia; Inflammation 43 1971
- Son et al. (2024), GPR55 Antagonist CID16020046 Attenuates Obesity-Induced Airway Inflammation by Suppressing Chronic Low-Grade Inflammation in the Lungs; Int. J. Mol. Sci. 25 7358
C25H19N3O4
>98% HPLC
NMR: (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
CID16020046 (834903-43-4) is a selective GPR55 antagonist.1 In HEK293 cells expressing GPR55, the compound behaves as an antagonist on lysophosphatidylinositol (LPI)-mediated Ca2+ release but was inactive on cells expressing CB1 and CB2. It blocks LPI-induced migration of colon cancer cells.2 It displays protective effects against oxidized LDL-induced inflammation3, mitigates advanced glycation end products-induced chondrocyte activation4, and displays anti-inflammatory effects in various cells5,6. A useful tool for studying the role of GPR55 in cellular physiology.
References/CItations:
- Kargl et al. (2013), A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function; J. Pharmacol. Exp. Ther. 346 54
- Kargl et al. (2016), GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis; Br. J. Pharmacol. 173 142
- Wang et al. (2020), The GPR55 antagonist CID16020046 protects against ox-LDL-induced inflammation in human aortic endothelial cells (HAECs); Arch. Biochem. Biophys. 681 108254
- Zeng et al. (2020), The GPR55 antagonist CID16020046 mitigates advanced glycation end products (AGEs)- induced chondrocyte activation; Chem. Biol. Interact. 325 109088
- Minamihata et al. (2020), Lysophosphatidylinositol, an Endogenous Ligand for G Protein-Coupled Receptor 55, Has Anti-inflammatory Effects in Cultured Microglia; Inflammation 43 1971
- Son et al. (2024), GPR55 Antagonist CID16020046 Attenuates Obesity-Induced Airway Inflammation by Suppressing Chronic Low-Grade Inflammation in the Lungs; Int. J. Mol. Sci. 25 7358
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
